Healthcare Industry News: metabolic disease
News Release - May 20, 2008
Biodel Inc. Announces Appointment of Alan Krasner, M.D. as Chief Medical OfficerDANBURY, Conn., May 20 (HSMN NewsFeed) -- Biodel Inc. (Nasdaq: BIOD ) today announced that Alan Krasner, M.D. has been appointed as the Company's Chief Medical Officer, effective May 27, 2008.
"The addition of Dr. Krasner to our team provides Biodel with strong internal clinical and regulatory leadership and we expect him to play an important role in the clinical development of our product candidates," said Dr. Solomon Steiner, Chief Executive Officer and Chairman of Biodel. "Dr. Krasner's depth of knowledge in endocrinology and insulin, coupled with his experience developing late stage drug candidates will be valuable in advancing our suite of VIAject(TM) products to market."
Dr. Andreas Pfuetzner, Biodel's current Chief Medical Officer will remain on Biodel's management team as the Company's Chief Medical Officer in Europe and as a member of the Company's Scientific Advisory Board.
"I look forward to working closely with my esteemed colleague to advance VIAject(TM) through the NDA phase of development," said Professor Dr. Andreas Pfuetzner.
Dr. Krasner joins the Company from Pfizer Global Research and Development where he was Director of the Department of Clinical Research metabolic diseases and responsible for the design, execution, clinical analysis, and reporting of multiple, global clinical trials supporting registration of late stage drug candidates. Dr. Krasner currently serves as a consulting physician at the Joslin Diabetes and Endocrinology Center of the Lawrence and Memorial Hospital in New London, Connecticut. Dr. Krasner holds a B.S. from the Medical Education Honors Program at Northwestern University and a M.D. from Northwestern University Medical School. He completed his residency at Johns Hopkins Hospital in internal medicine and subsequently received a fellowship from Johns Hopkins Hospital in endocrinology and metabolism.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at www.biodel.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.